JP2017524652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524652A5 JP2017524652A5 JP2016568591A JP2016568591A JP2017524652A5 JP 2017524652 A5 JP2017524652 A5 JP 2017524652A5 JP 2016568591 A JP2016568591 A JP 2016568591A JP 2016568591 A JP2016568591 A JP 2016568591A JP 2017524652 A5 JP2017524652 A5 JP 2017524652A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dose
- item
- multiple myeloma
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 49
- 201000011510 cancer Diseases 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 20
- 208000034578 Multiple myelomas Diseases 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 238000011275 oncology therapy Methods 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000002955 immunomodulating agent Substances 0.000 claims description 10
- 229940121354 immunomodulator Drugs 0.000 claims description 10
- 230000002584 immunomodulator Effects 0.000 claims description 10
- 238000009115 maintenance therapy Methods 0.000 claims description 10
- 239000003207 proteasome inhibitor Substances 0.000 claims description 10
- 238000011476 stem cell transplantation Methods 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 4
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims description 4
- 229960004942 lenalidomide Drugs 0.000 claims description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 2
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 108010064641 ONX 0912 Proteins 0.000 claims description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229960002438 carfilzomib Drugs 0.000 claims description 2
- 108010021331 carfilzomib Proteins 0.000 claims description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229960002563 disulfiram Drugs 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229960003648 ixazomib Drugs 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229950002736 marizomib Drugs 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 claims description 2
- 229950005750 oprozomib Drugs 0.000 claims description 2
- 229960000688 pomalidomide Drugs 0.000 claims description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 claims description 2
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 235000012222 talc Nutrition 0.000 claims description 2
- 238000011269 treatment regimen Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108700002672 epoxomicin Proteins 0.000 claims 1
- DOGIDQKFVLKMLQ-JTHVHQAWSA-N epoxomicin Chemical compound CC[C@H](C)[C@H](N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 DOGIDQKFVLKMLQ-JTHVHQAWSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019104381A JP6906564B2 (ja) | 2014-05-20 | 2019-06-04 | 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000991P | 2014-05-20 | 2014-05-20 | |
| US62/000,991 | 2014-05-20 | ||
| US201462019600P | 2014-07-01 | 2014-07-01 | |
| US62/019,600 | 2014-07-01 | ||
| US201462088154P | 2014-12-05 | 2014-12-05 | |
| US62/088,154 | 2014-12-05 | ||
| PCT/US2015/031633 WO2015179443A1 (en) | 2014-05-20 | 2015-05-19 | Boron-containing proteasome inhibitors for use after primary cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019104381A Division JP6906564B2 (ja) | 2014-05-20 | 2019-06-04 | 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017524652A JP2017524652A (ja) | 2017-08-31 |
| JP2017524652A5 true JP2017524652A5 (enExample) | 2018-06-28 |
Family
ID=54554652
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568591A Pending JP2017524652A (ja) | 2014-05-20 | 2015-05-19 | 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 |
| JP2019104381A Active JP6906564B2 (ja) | 2014-05-20 | 2019-06-04 | 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019104381A Active JP6906564B2 (ja) | 2014-05-20 | 2019-06-04 | 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20150335668A1 (enExample) |
| EP (1) | EP3145526A1 (enExample) |
| JP (2) | JP2017524652A (enExample) |
| KR (2) | KR102509950B1 (enExample) |
| CN (1) | CN106659761A (enExample) |
| AU (2) | AU2015264272A1 (enExample) |
| BR (1) | BR112016026774A8 (enExample) |
| CA (1) | CA2949517A1 (enExample) |
| CL (1) | CL2016002948A1 (enExample) |
| CR (1) | CR20160577A (enExample) |
| EA (1) | EA201692332A1 (enExample) |
| IL (2) | IL249025B (enExample) |
| MA (1) | MA39964A (enExample) |
| MX (2) | MX2016015267A (enExample) |
| PH (1) | PH12016502301A1 (enExample) |
| SG (2) | SG11201609259VA (enExample) |
| TN (1) | TN2016000492A1 (enExample) |
| TW (1) | TWI746422B (enExample) |
| UA (1) | UA121389C2 (enExample) |
| UY (1) | UY36132A (enExample) |
| WO (1) | WO2015179443A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108472304A (zh) * | 2015-11-04 | 2018-08-31 | 千年药物公司 | 用于鉴定、评价和治疗患有多发性骨髓瘤的患者的方法 |
| CN109562084A (zh) * | 2016-08-04 | 2019-04-02 | 米伦纽姆医药公司 | 蛋白酶体抑制剂和抗cd30抗体的组合 |
| AU2017386771A1 (en) * | 2016-12-28 | 2019-06-20 | Daiichi Sankyo Company, Limited | Therapeutic drug for Alport's syndrome |
| WO2019020099A1 (zh) | 2017-07-28 | 2019-01-31 | 成都地奥九泓制药厂 | 一种硼酸酯化合物、其合成方法及其用途 |
| EP4444726A4 (en) * | 2021-12-06 | 2025-11-26 | Pretzel Therapeutics Inc | LONP1 INHIBITORS, USES AND METHODS |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2160413A (en) | 1935-04-16 | 1939-05-30 | Schering Ag | Polyiodo derivatives of acylamino acids and their salts and a method of making the same |
| NZ203706A (en) | 1982-04-22 | 1986-03-14 | Squibb & Sons Inc | Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment |
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| JPS6233170A (ja) | 1985-08-07 | 1987-02-13 | Tokuyama Soda Co Ltd | 環状ポリエ−テル化合物 |
| JPH0813759B2 (ja) | 1986-09-01 | 1996-02-14 | 富士写真フイルム株式会社 | アルコキシベンゼン誘導体の製造方法 |
| JP2512303B2 (ja) | 1987-03-20 | 1996-07-03 | 呉羽化学工業株式会社 | ２−オキサゾリン−４，５−ジオンのフエニルヒドラゾン誘導体 |
| US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
| US5159060A (en) | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| DE3827340A1 (de) | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
| MX9206628A (es) | 1991-11-22 | 1993-05-01 | Boehringer Ingelheim Pharma | Ester de prolinaboronato y metodo para su preparacion. |
| US5442100A (en) | 1992-08-14 | 1995-08-15 | The Procter & Gamble Company | β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids |
| EP0583536B1 (en) | 1992-08-14 | 1997-03-05 | The Procter & Gamble Company | Liquid detergents containing an alpha-amino boronic acid |
| US5492900A (en) | 1993-09-10 | 1996-02-20 | Neutron Technology Corporation | Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA) |
| US5935944A (en) | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
| US6060462A (en) | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
| FR2712602B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
| US5574017A (en) | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5614649A (en) | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
| US5834487A (en) | 1996-09-24 | 1998-11-10 | Cv Therapeutics | Inhibition of 26S and 20S proteasome by indanones |
| AU741802B2 (en) | 1997-02-15 | 2001-12-13 | Millennium Pharmaceuticals, Inc. | Treatment of infarcts through inhibition of NF-kappaB |
| CA2304622A1 (en) | 1997-09-25 | 1999-04-01 | Proscript, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-?b via the ubiquitin proteasome pathway to treat inflammatory and autoimmunediseases |
| CA2314259A1 (en) | 1997-12-16 | 1999-06-24 | Robert Siman | Multicatalytic protease inhibitors for use as anti-tumor agents |
| US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
| WO2000024392A1 (en) | 1998-10-26 | 2000-05-04 | Sumitomo Pharmaceuticals Company, Limited | β-AMYLOID FORMATION INHIBITORS |
| US6169076B1 (en) | 1999-03-31 | 2001-01-02 | Glcosyn Pharmaceuticals, Inc. | P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols |
| EP1196436A2 (en) | 1999-07-07 | 2002-04-17 | Bristol-Myers Squibb Pharma Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| SE0100714D0 (sv) | 2000-07-13 | 2001-02-28 | Ap Biotech Ab | Reaction vessel and method for distributing fluid in such a vessel |
| US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
| JP2002145848A (ja) | 2000-11-10 | 2002-05-22 | Kyorin Pharmaceut Co Ltd | アルケニルアミノ酸誘導体及びその製造法 |
| JP4162491B2 (ja) | 2001-01-25 | 2008-10-08 | アメリカ合衆国 | ボロン酸化合物製剤 |
| US6933290B2 (en) | 2001-05-30 | 2005-08-23 | Novartis Ag | 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives |
| WO2003033506A1 (en) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Aminoborane acid derivative and proteasome inhibitory drug containing the same |
| JPWO2003033507A1 (ja) | 2001-10-12 | 2005-02-03 | 杏林製薬株式会社 | ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬 |
| WO2003059898A2 (en) | 2002-01-08 | 2003-07-24 | Eisai Co. Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
| AU2003223930A1 (en) | 2002-06-14 | 2003-12-31 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
| US20060084592A1 (en) | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
| TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| GB0405267D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
| ATE521612T1 (de) | 2004-03-30 | 2011-09-15 | Millennium Pharm Inc | Synthese von boronsäureester- und boronsäureverbindungen |
| EP1758921A2 (en) | 2004-05-10 | 2007-03-07 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
| TW200618820A (en) | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
| US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| EP1874297A4 (en) | 2005-04-29 | 2009-04-22 | Kosan Biosciences Inc | METHOD OF TREATING MULTIPLE MYELOMES USING 17AGENE OR 17-AG OR A PRODRUG OR ALL IN COMBINATION WITH A PROTEASOMIC INHIBITOR |
| KR20080030079A (ko) | 2005-07-05 | 2008-04-03 | 트러스티즈 오브 터프츠 칼리지 | 섬유아세포 활성 단백질 알파의 억제제 |
| US20090304631A1 (en) | 2006-01-27 | 2009-12-10 | David Alan Campbell | Hepatitis c serine protease inhibitors and uses therefor |
| CL2007002499A1 (es) | 2006-08-30 | 2008-03-14 | Phenomix Corp | Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes. |
| WO2009006473A2 (en) | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
| EA028622B1 (ru) | 2007-08-06 | 2017-12-29 | Милленниум Фармасьютикалз, Инк. | Ингибиторы протеасом |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| GEP201706703B (en) | 2008-06-17 | 2017-07-25 | Millennium Pharmaceuticals Inc (A Delaware Corporation) | Boronate ester compounds and pharmaceutical compositions thereof |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| US8513218B2 (en) | 2010-03-31 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
-
2015
- 2015-05-19 KR KR1020227022220A patent/KR102509950B1/ko active Active
- 2015-05-19 WO PCT/US2015/031633 patent/WO2015179443A1/en not_active Ceased
- 2015-05-19 CR CR20160577A patent/CR20160577A/es unknown
- 2015-05-19 AU AU2015264272A patent/AU2015264272A1/en not_active Abandoned
- 2015-05-19 TN TN2016000492A patent/TN2016000492A1/en unknown
- 2015-05-19 MX MX2016015267A patent/MX2016015267A/es unknown
- 2015-05-19 JP JP2016568591A patent/JP2017524652A/ja active Pending
- 2015-05-19 CA CA2949517A patent/CA2949517A1/en not_active Abandoned
- 2015-05-19 UY UY0001036132A patent/UY36132A/es not_active Application Discontinuation
- 2015-05-19 SG SG11201609259VA patent/SG11201609259VA/en unknown
- 2015-05-19 UA UAA201612860A patent/UA121389C2/uk unknown
- 2015-05-19 KR KR1020167033753A patent/KR102481856B1/ko active Active
- 2015-05-19 TW TW104115971A patent/TWI746422B/zh active
- 2015-05-19 EP EP15726483.9A patent/EP3145526A1/en not_active Withdrawn
- 2015-05-19 MA MA039964A patent/MA39964A/fr unknown
- 2015-05-19 SG SG10202003693RA patent/SG10202003693RA/en unknown
- 2015-05-19 BR BR112016026774A patent/BR112016026774A8/pt not_active Application Discontinuation
- 2015-05-19 EA EA201692332A patent/EA201692332A1/ru unknown
- 2015-05-19 CN CN201580029362.6A patent/CN106659761A/zh active Pending
- 2015-05-19 US US14/716,761 patent/US20150335668A1/en not_active Abandoned
-
2016
- 2016-11-17 IL IL249025A patent/IL249025B/en active IP Right Grant
- 2016-11-17 PH PH12016502301A patent/PH12016502301A1/en unknown
- 2016-11-18 MX MX2021009044A patent/MX2021009044A/es unknown
- 2016-11-18 CL CL2016002948A patent/CL2016002948A1/es unknown
-
2018
- 2018-12-21 US US16/229,524 patent/US20190125773A1/en not_active Abandoned
-
2019
- 2019-06-04 JP JP2019104381A patent/JP6906564B2/ja active Active
- 2019-07-22 US US16/517,963 patent/US20190343851A1/en not_active Abandoned
-
2020
- 2020-02-04 US US16/781,432 patent/US20200171061A1/en not_active Abandoned
- 2020-04-19 IL IL274042A patent/IL274042A/en unknown
-
2021
- 2021-01-20 AU AU2021200370A patent/AU2021200370B2/en not_active Ceased
- 2021-03-01 US US17/188,492 patent/US11241448B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524652A5 (enExample) | ||
| JP2014532704A5 (enExample) | ||
| JP2018506550A5 (enExample) | ||
| JP2015212268A5 (enExample) | ||
| JP6906564B2 (ja) | 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 | |
| AR068897A1 (es) | Inhibidores de proteasoma | |
| JP2018530578A5 (enExample) | ||
| JP2011520846A5 (enExample) | ||
| RU2010151660A (ru) | Способы лечения множественной миеломы | |
| JP2017533220A5 (enExample) | ||
| JP2014507475A5 (enExample) | ||
| PH12013500173A1 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
| JP2014148552A5 (enExample) | ||
| JP2016531853A5 (enExample) | ||
| JPWO2020210418A5 (enExample) | ||
| JP2018505901A5 (enExample) | ||
| RU2016145411A (ru) | Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости | |
| RU2012136190A (ru) | Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента | |
| JP2016514142A5 (enExample) | ||
| Jia Ruan et al. | Management of relapsed mantle cell lymphoma: still a treatment challenge | |
| JP2016514143A5 (enExample) | ||
| JP2018512394A5 (enExample) | ||
| MD20160131A2 (ro) | Compus de tiacumicină şi regim de tratament asociat | |
| Maeda | Nausea: case report | |
| Stevenson | Dabigatran etexilate/rivaroxaban |